PMID- 10432405
OWN - NLM
STAT- MEDLINE
DCOM- 19990830
LR  - 20061115
IS  - 0085-2538 (Print)
IS  - 0085-2538 (Linking)
VI  - 56
IP  - 2
DP  - 1999 Aug
TI  - Serum and urinary concentrations of heparan sulfate in patients with diabetic
      nephropathy.
PG  - 650-8
AB  - BACKGROUND: Heparan sulfate (HS) contributes to the negative charge in the
      glomerular basement membrane (GBM), which may maintain the GBM charge barrier.
      Changes in sulfation and/or the concentration of HS may be associated with the
      development of diabetic nephropathy. METHODS: Using two different antibodies
      specific for HS chains, one that reacts with the N-sulfated sequences in HS
      chains (10E4) and the other that reacts with neo-epitope of HS, which occurs
      after heparitinase digestion of HS chains (3G10), we examined the serum and
      urinary concentrations of HS by enzyme-linked immunosorbent assay and performed
      immunohistochemical staining of glomeruli in diabetic patients with and without
      nephropathy. RESULTS: The level of urinary excretion of 10E4 binding
      HS/creatinine clearance was significantly reduced in diabetic patients when
      compared with that in nondiabetic subjects (P < 0.0001), and the level was more
      decreased in patients with overt nephropathy than in patients without overt
      nephropathy. No differences or only small differences were found between these
      groups in serum and urinary 3G10-binding HS and in serum 10E4-binding HS.
      Immunohistochemical staining with these antibodies was consistent with the
      findings in the urine. CONCLUSIONS: The results suggest that a decreased HS
      N-sulfation exists in the urine, which may reflect a structural change or an
      altered processing of HS within the GBM. Because N-sulfation plays a key role in 
      determining the extent of sulfation within the HS chains, the decreased urinary
      10E4-binding HS may have potential implications with regard to the development of
      diabetic nephropathy.
FAU - Yokoyama, H
AU  - Yokoyama H
AD  - Diabetes Center, Tokyo Women's Medical University School of Medicine and Nomura
      Hospital, Japan.
FAU - Sato, K
AU  - Sato K
FAU - Okudaira, M
AU  - Okudaira M
FAU - Morita, C
AU  - Morita C
FAU - Takahashi, C
AU  - Takahashi C
FAU - Suzuki, D
AU  - Suzuki D
FAU - Sakai, H
AU  - Sakai H
FAU - Iwamoto, Y
AU  - Iwamoto Y
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Kidney Int
JT  - Kidney international
JID - 0323470
RN  - 0 (Epitopes)
RN  - 0 (Sulfates)
RN  - 9050-30-0 (Heparitin Sulfate)
RN  - EC 4.2.2.- (Polysaccharide-Lyases)
RN  - EC 4.2.2.8 (heparitinsulfate lyase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibody Specificity
MH  - Basement Membrane/chemistry/metabolism
MH  - Diabetes Mellitus, Type 2/complications/*metabolism
MH  - Diabetic Nephropathies/*metabolism
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Epitopes/immunology
MH  - Extracellular Matrix/metabolism
MH  - Female
MH  - Heparitin Sulfate/*blood/immunology/*urine
MH  - Humans
MH  - Kidney Glomerulus/chemistry/metabolism
MH  - Male
MH  - Middle Aged
MH  - Polysaccharide-Lyases/pharmacology
MH  - Sulfates/metabolism
EDAT- 1999/08/05 00:00
MHDA- 1999/08/05 00:01
CRDT- 1999/08/05 00:00
PHST- 1999/08/05 00:00 [pubmed]
PHST- 1999/08/05 00:01 [medline]
PHST- 1999/08/05 00:00 [entrez]
AID - S0085-2538(15)46336-7 [pii]
AID - 10.1046/j.1523-1755.1999.00591.x [doi]
PST - ppublish
SO  - Kidney Int. 1999 Aug;56(2):650-8. doi: 10.1046/j.1523-1755.1999.00591.x.